8.610CAD+1.77%Mkt Cap: 845.32M CADP/E: 143.50Last update: 2026-06-05
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refr…
Industry Peers
Drug Manufacturers - Specialty & Generic155.09BSEKP/E 169.8
59.50BEURP/E 23.5
57.56BTRY—
33.03BPLNP/E 21.6
23.34BUSDP/E 20.3
18.49BUSD—
16.48BUSDP/E 25.2
13.07BTRY—
Indicators:|
Key Statistics
Company
Market Cap845.32M CAD
Enterprise Value771.92M CAD
Revenue (TTM)510.45M CAD
Gross Profit200.23M CAD
Net Income (TTM)-5.37M CAD
Revenue/Share5.142 CAD
Last Price8.610 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees830
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)143.50
P/E (Forward)33.12
PEG—
EV/EBITDA11.01
EV/Revenue1.51
P/S1.66
P/B1.07
EPS (TTM)0.06
EPS (Forward)0.26
52W Range
5.66091% of range8.900
52W High8.900 CAD
52W Low5.660 CAD
Profitability
Gross Margin44.49%
Oper. Margin7.13%
EBITDA Margin13.74%
Profit Margin-1.19%
ROE-0.70%
ROA-0.51%
Growth
Revenue Growth68.50%
Earnings Growth550.00%
Cash Flow & Leverage
Operating CF68.96M CAD
CapEx (TTM)33.69M CAD
FCF Margin13.01%
FCF Yield7.86%
Net Debt-73.41M CAD
Net Debt/EBITDA-1.05
Balance Sheet
Debt/Equity0.10
Current Ratio2.32
Quick Ratio1.56
Book Value/Sh8.013 CAD
Cash/Share1.458 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)9.829 CAD
Target Range9.000 CAD – 12.00 CAD
# Analysts7
Ownership
Shares Out.98.18M
Float60.24M
Insiders46.95%
Institutions20.08%
Short Interest
Short Ratio16.9d
Short % Out.1.76%
Shares Short1.80M
Short (prev mo.)1.86M
Technical
SMA 507.800 (+10.4%)
SMA 2006.512 (+32.2%)
Beta0.07
S&P 52W Chg27.18%
Avg Vol (30d)93.34K
Avg Vol (10d)66.96K
Technical Indicators
RSI (14)65.3
MACD0.1617
MACD Signal0.1708
MACD Hist.-0.0091
BB Upper8.784 CAD
BB Middle8.360 CAD
BB Lower7.935 CAD
BB Width10.16%
ATR (14)0.2545 CAD
Vol Ratio (20d)2.04x